The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiation

被引:12
|
作者
de Boer, Esther C. W. [1 ,2 ,3 ]
Thielen, Astrid J. F. [1 ,2 ]
Langereis, Jeroen D. [4 ,5 ]
Kamp, Angela [1 ,2 ]
Brouwer, Mieke C. [1 ,2 ]
Oskam, Nienke [1 ,2 ]
Jongsma, Marlieke L. [1 ,2 ]
Baral, April J. [6 ]
Spaapen, Robbert M. [1 ,2 ]
Zeerleder, Sacha [1 ,2 ,7 ,8 ]
Vidarsson, Gestur [2 ,9 ]
Rispens, Theo [1 ,2 ]
Wouters, Diana [1 ,2 ,10 ]
Pouw, Richard B. [1 ,2 ,11 ]
Jongerius, Ilse [1 ,2 ,3 ]
机构
[1] Univ Amsterdam, Amsterdam Infect & Immun Inst, Dept Immunopathol, Sanquin Res,Med Ctr, Amsterdam, Netherlands
[2] Univ Amsterdam, Amsterdam Infect & Immun Inst, Landsteiner Lab, Med Ctr, Amsterdam, Netherlands
[3] Univ Amsterdam, Emma Childrens Hosp, Dept Pediat Immunol Rheumatol & Infect Dis, Med Ctr, Amsterdam, Netherlands
[4] Radboudumc, Radboud Inst Mol Life Sci, Lab Med Immunol, Nijmegen, Netherlands
[5] Radboudumc, Radboud Ctr Infect Dis, Nijmegen, Netherlands
[6] Translat & Clin Res Inst, Newcastle Upon Tyne, England
[7] Luzern & Univ Bern, Dept Hematol, Luzerner Kantonsspital, Bern, Switzerland
[8] Univ Bern, Dept Biomed Res, Bern, Switzerland
[9] Univ Amsterdam, Dept Expt Immunohematol, Sanquin Res, Med Ctr, Amsterdam, Netherlands
[10] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands
[11] Sanquin Res, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands
关键词
alternative pathway; amplification loop; antibodies; autoimmune haemolytic anaemia; classical pathway; complement activation; FACTOR B; INHIBITOR; ANTIBODIES; HEXAMERS; DISEASE; FAMILY; DESTRUCTION; DEPOSITION; MUTATIONS; COMPONENT;
D O I
10.1002/cti2.1436
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
ObjectivesThe complement system is an important component of innate immunity. The alternative pathway (AP) amplification loop is considered an essential feed forward mechanism for complement activation. However, the role of the AP in classical pathway (CP) activation has only been studied in ELISA settings. Here, we investigated its contribution on physiologically relevant surfaces of human cells and bacterial pathogens and in antibody-mediated complement activation, including in autoimmune haemolytic anaemia (AIHA) setting with autoantibodies against red blood cells (RBCs). MethodsWe evaluated the contribution of the AP to complement responses initiated through the CP on human RBCs by serum of AIHA patients and recombinant antibodies. Moreover, we studied complement activation on Neisseria meningitidis and Escherichia coli. The effect of the AP was examined using either AP-depleted sera or antibodies against factor B and factor D. ResultsWe show that the amplification loop is redundant when efficient CP activation takes place. This is independent of the presence of membrane-bound complement regulators. The role of the AP may become significant when insufficient CP complement activation occurs, but this depends on antibody levels and (sub)class. Our data indicate that therapeutic intervention in the amplification loop will most likely not be effective to treat antibody-mediated diseases. ConclusionThe AP can be bypassed through efficient CP activation. The AP amplification loop has a role in complement activation during conditions of modest activation via the CP, when it can allow for efficient complement-mediated killing.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] THE ROLE OF ANTIBODY IN THE ACTIVATION OF THE ALTERNATIVE COMPLEMENT PATHWAY
    RATNOFF, WD
    FEARON, DT
    AUSTEN, KF
    SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 1983, 6 (04): : 361 - 371
  • [32] RESTRICTION OF ALTERNATIVE COMPLEMENT PATHWAY ACTIVATION BY SIALOSYLGLYCOLIPIDS
    OKADA, N
    YASUDA, T
    OKADA, H
    NATURE, 1982, 299 (5880) : 261 - 263
  • [33] ACTIVATION OF THE ALTERNATIVE PATHWAY OF HUMAN-COMPLEMENT
    KAZATCHKINE, M
    FISCHER, E
    NYDEGGER, U
    ANNALES D IMMUNOLOGIE, 1982, C133 (02): : 181 - 188
  • [34] Bacteriolytic activity of the alternative pathway of complement differs kinetically from the classical pathway
    Kilpi, Maaria K.
    Atosuo, Janne T.
    Lilius, Esa-Matti E.
    DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY, 2009, 33 (10): : 1102 - 1110
  • [35] SOLUBILIZATION OF IMMUNE-COMPLEXES BY COMPLEMENT ACTIVATED BY ALTERNATIVE PATHWAY BUT NOT BY CLASSICAL PATHWAY
    TAKAHASHI, M
    BRADE, V
    NUSSENZWEIG, V
    FEDERATION PROCEEDINGS, 1976, 35 (03) : 254 - 254
  • [36] INCREASED ACTIVATION OF THE ALTERNATIVE COMPLEMENT PATHWAY IN SICKLE-CELL DISEASE
    CHUDWIN, DS
    KORENBLIT, AD
    KINGZETTE, M
    ARTRIP, S
    RAO, S
    CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1985, 37 (01): : 93 - 97
  • [37] Curvature of Synthetic and Natural Surfaces Is an Important Target Feature in Classical Pathway Complement Activation
    Pedersen, Martin Bjerregard
    Zhou, Xingfei
    Larsen, Esben Kjaer Unmack
    Sorensen, Uffe Skov
    Kjems, Jorgen
    Nygaard, Jens Vinge
    Nyengaard, Jens Randel
    Meyer, Rikke Louise
    Boesen, Thomas
    Vorup-Jensen, Thomas
    JOURNAL OF IMMUNOLOGY, 2010, 184 (04): : 1931 - 1945
  • [38] Activation of alternative complement pathway without complement factor D
    Zhang, Yuzhou
    Keenan, Adam
    Lindorfer, Margaret A.
    Pitcher, Gabriella R.
    Taylor, Ronald P.
    Lambris, John D.
    Smith, Richard J. H.
    MOLECULAR IMMUNOLOGY, 2017, 89 : 173 - 173
  • [39] ACTIVATION OF THE CLASSICAL COMPLEMENT PATHWAY BY NEPHRITIC FACTOR BOUND TO THE ALTERNATIVE PATHWAY C3-C5 CONVERTASE
    SOBEL, AT
    COOPER, NR
    SCHREIBER, RD
    JOURNAL OF IMMUNOLOGY, 1979, 122 (01): : 34 - 38
  • [40] INITIATION OF THE CLASSICAL COMPLEMENT PATHWAY - CONTROL OF ACTIVATOR MEDIATED AND SPONTANEOUS C1 ACTIVATION
    ZICCARDI, RJ
    MOLECULAR IMMUNOLOGY, 1982, 19 (11) : 1413 - 1413